Literature DB >> 15030991

Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis.

Daniel F Wallace1, Roslyn M Clark, Hugh A J Harley, V Nathan Subramaniam.   

Abstract

We report the identification of a novel mutation in ferroportin1 in an Australian family with autosomal dominant iron overload. The phenotype of iron overload in one member of this family is associated with high serum ferritin concentration and elevated transferrin saturation. The pattern of iron overload in the liver shows accumulation predominantly in parenchymal cells with some Kupffer cell iron loading. Although some cases of type 4 haemochromatosis have been associated with the development of liver fibrosis this is the first report of a patient with fully established cirrhosis at a relatively young age (32 years). The coexistence of sarcoidosis in this patient may contribute to the more severe phenotype. This report highlights the phenotypic variability that can occur in type 4 haemochromatosis. Some patients have predominant reticuloendothelial iron loading and normal transferrin saturation whereas others have predominant parenchymal iron loading and elevated transferrin saturation. The reasons for this variability remain to be determined. Interestingly this is the third mutation to affect asparagine 144, reinforcing the important role for this amino acid in the function of ferroportin1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15030991     DOI: 10.1016/j.jhep.2003.12.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  15 in total

1.  Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.

Authors:  Sharraya Aschemeyer; Bo Qiao; Deborah Stefanova; Erika V Valore; Albert C Sek; T Alex Ruwe; Kyle R Vieth; Grace Jung; Carla Casu; Stefano Rivella; Mika Jormakka; Bryan Mackenzie; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2017-12-13       Impact factor: 22.113

2.  The molecular basis of ferroportin-linked hemochromatosis.

Authors:  Ivana De Domenico; Diane McVey Ward; Elizabeta Nemeth; Michael B Vaughn; Giovanni Musci; Tomas Ganz; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-13       Impact factor: 11.205

3.  Ferroportin1 is required for normal iron cycling in zebrafish.

Authors:  Paula G Fraenkel; David Traver; Adriana Donovan; David Zahrieh; Leonard I Zon
Journal:  J Clin Invest       Date:  2005-05-05       Impact factor: 14.808

4.  Wild-type and mutant ferroportins do not form oligomers in transfected cells.

Authors:  Ana Sofia Gonçalves; Françoise Muzeau; Rand Blaybel; Gilles Hetet; Fathi Driss; Constance Delaby; François Canonne-Hergaux; Carole Beaumont
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

5.  The molecular basis of hepcidin-resistant hereditary hemochromatosis.

Authors:  Augustine Fernandes; Gloria C Preza; Yen Phung; Ivana De Domenico; Jerry Kaplan; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2009-04-21       Impact factor: 22.113

Review 6.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

Review 7.  Recent advances in understanding haemochromatosis: a transition state.

Authors:  K J H Robson; A T Merryweather-Clarke; E Cadet; V Viprakasit; M G Zaahl; J J Pointon; D J Weatherall; J Rochette
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

8.  Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter.

Authors:  Adrian E Rice; Michael J Mendez; Craig A Hokanson; Douglas C Rees; Pamela J Björkman
Journal:  J Mol Biol       Date:  2009-01-03       Impact factor: 5.469

Review 9.  Targeting iron metabolism in drug discovery and delivery.

Authors:  Bart J Crielaard; Twan Lammers; Stefano Rivella
Journal:  Nat Rev Drug Discov       Date:  2017-02-03       Impact factor: 84.694

Review 10.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.